Clinical Trial Update: A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma [Phase 3]

View source ↗

Summary

A Phase 3 trial is evaluating the efficacy, safety and tolerability of FF/UMEC/VI versus FF/VI in adolescents aged 12-17 with asthma. The study is currently rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• FF/UMEC/VI (fluticasone furoate/umeclidinium/vilanterol)
• FF/VI (fluticasone furoate/vilanterol)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Asthma | Phase 3 | Status: RECRUITING